Frequencies of CD33+CD11b+HLA-DR­CD14­CD66b+ and CD33+CD11b+HLA-DR­CD14+CD66b­ Cells in Peripheral Blood as Severity Immune Biomarkers in COVID-19

Common clinical features of patients with Coronavirus disease-2019 (COVID-19) vary from fever, to acute severe respiratory distress syndrome. Several laboratory parameters are reported as indicators of COVID-19 severity. We hereby describe the possible novel severity biomarkers for COVID-19, CD11b+CD33+HLA-DR-CD14+ cells and CD11b+CD33+HLA-DR-CD66b+ cells.